{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:01:05Z","timestamp":1787162465044,"version":"build-2736575974"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institutes of Health National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19 Grant ( AI128910 )"],"award-info":[{"award-number":["U19 Grant ( AI128910 )"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.it.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:35:22Z","timestamp":1783485322000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adenosine as a metabolic checkpoint in CD8+ T cell dysfunction"],"prefix":"10.1016","author":[{"given":"Arden O.","family":"Edgerton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio J.","family":"Reginato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele A.","family":"Kutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6924-4300","authenticated-orcid":false,"given":"Eilas K.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2026.06.005_bb0005","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8+ T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005661","article-title":"Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection","volume":"12","author":"Hoffmann","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2026.06.005_bb0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.it.2026.06.005_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/v16020219","article-title":"Examining chronic inflammation, immune metabolism, and T cell dysfunction in HIV infection","volume":"16","author":"Mu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.it.2026.06.005_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1676702","article-title":"Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation","volume":"16","author":"Majumder","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11302-018-9619-2","article-title":"Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection","volume":"14","author":"Passos","year":"2018","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.it.2026.06.005_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40364-025-00784-0","article-title":"The progress and prospects of targeting the adenosine pathway in cancer immunotherapy","volume":"13","author":"Yang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.it.2026.06.005_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1111369","article-title":"The adenosinergic machinery in cancer: in-tandem insights from basic mechanisms to therapy","volume":"14","author":"Kang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0050","article-title":"The adenosine pathway and human immunodeficiency virus-associated inflammation. Open Forum","volume":"8","author":"Hixson","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.it.2026.06.005_bb0055","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11033-024-09839-1","article-title":"Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS","volume":"51","author":"Atif","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.it.2026.06.005_bb0060","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.3390\/ijms22147685","article-title":"adenosine and inflammation: here, there and everywhere","volume":"22","author":"Pasquini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.it.2026.06.005_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/sji.70038","article-title":"adenosine and adenosine deaminase contrary manifestations in immunity","volume":"102","author":"Mardanyan","year":"2025","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0070","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/ijms19041222","article-title":"Mechanisms of ATP release by inflammatory cells","volume":"19","author":"Dosch","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.it.2026.06.005_bb0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11302-013-9357-4","article-title":"Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses","volume":"9","author":"Jacob","year":"2013","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.it.2026.06.005_bb0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","article-title":"Cellular function and molecular structure of ecto-nucleotidases","volume":"8","author":"Zimmermann","year":"2012","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.it.2026.06.005_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-immunol-051116-052406","article-title":"Purine release, metabolism, and signaling in the inflammatory response","volume":"37","author":"Linden","year":"2019","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2018.04.006","article-title":"Adenosine signaling and the immune system: when a lot could be too much","volume":"205","author":"Antonioli","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.it.2026.06.005_bb0095","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","article-title":"Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion","volume":"90","author":"Huang","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.06.005_bb0100","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.febslet.2011.04.036","article-title":"NAD+-metabolizing ecto-enzymes shape tumor\u2013host interactions: the chronic lymphocytic leukemia model","volume":"585","author":"Vaisitti","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.it.2026.06.005_bb0105","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.it.2026.06.005_bb0110","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41467-019-08801-1","article-title":"Adenosine deaminase-1 delineates human follicular helper T cell function and is altered with HIV","volume":"10","author":"Tardif","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.06.005_bb0115","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jaip.2023.01.028","article-title":"Long-term immune reconstitution in ADA-deficient patients treated with elapegademase: a real-world experience","volume":"11","author":"Murguia-Favela","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.it.2026.06.005_bb0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.2018892752","article-title":"Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2","volume":"134","author":"Carmona-Rivera","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.06.005_bb0125","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.clinbiochem.2011.05.020","article-title":"Analysis of serum adenosine deaminase (ADA) and ADA1 and ADA2 isoenzyme activities in HIV positive and HIV\u2013HBV co-infected patients","volume":"44","author":"Khodadadi","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.it.2026.06.005_bb0130","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.4049\/jimmunol.155.10.4630","article-title":"Expression of ecto-adenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. possible role of adenosine deaminase as costimulatory molecule","volume":"155","author":"Martin","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0135","doi-asserted-by":"crossref","first-page":"9583","DOI":"10.1073\/pnas.0501050102","article-title":"CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse","volume":"102","author":"Pacheco","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2026.06.005_bb0140","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.vaccine.2020.03.047","article-title":"Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 envelope DNA and protein vaccines","volume":"38","author":"Gary","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.it.2026.06.005_bb0145","doi-asserted-by":"crossref","first-page":"04","DOI":"10.4049\/jimmunol.206.Supp.30.04","article-title":"Determining adenosine deaminase 1 (ADA-1) impact on immune memory and durability as a molecular adjuvant in a SARS-CoV-2 DNA vaccine formulation","volume":"206","author":"Cusimano","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108300","article-title":"Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: potential therapeutic opportunities","volume":"240","author":"Kaur","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.it.2026.06.005_bb0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters\u2014a review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.it.2026.06.005_bb0160","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41590-025-02153-3","article-title":"Inhibition of ENT1 relieves intracellular adenosine-mediated Tcell suppression in cancer","volume":"26","author":"Sanders","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/pharmrev.121.000528","article-title":"ATP and adenosine metabolism in cancer: exploitation for therapeutic gain","volume":"74","author":"Yegutkin","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.it.2026.06.005_bb0170","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/biom12030418","article-title":"Adenosine-metabolizing enzymes, adenosine kinase and adenosine deaminase, in cancer","volume":"12","author":"Zhulai","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.it.2026.06.005_bb0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fimmu.2013.00085","article-title":"Regulation of inflammation by adenosine","volume":"4","author":"Hasko","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd2638","article-title":"Adenosine receptors: therapeutic aspects for inflammatory and immune diseases","volume":"7","author":"Hasko","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.06.005_bb0185","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0006-2952(00)00570-0","article-title":"Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in chinese hamster ovary cells","volume":"61","author":"Fredholm","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.it.2026.06.005_bb0190","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/414916a","article-title":"Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage","volume":"414","author":"Ohta","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.it.2026.06.005_bb0195","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1158\/0008-5472.CAN-06-4249","article-title":"Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase a type I signaling","volume":"67","author":"Raskovalova","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0200","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","article-title":"Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models","volume":"67","author":"Leone","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.06.005_bb0205","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fimmu.2012.00190","article-title":"The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway","volume":"3","author":"Ohta","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0210","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","article-title":"Extracellular adenosine-mediated modulation of regulatory T cells","volume":"5","author":"Ohta","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0215","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4049\/jimmunol.174.2.1073","article-title":"A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells","volume":"174","author":"Lappas","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0220","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2026.06.005_bb0225","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-017-0665-0","article-title":"Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma","volume":"16","author":"Ma","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.06.005_bb0235","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3389\/fimmu.2019.02465","article-title":"Expression of CD39 is correlated with HIV DNA levels in na\u00efve Tregs in chronically infected ART na\u00efve patients","volume":"10","author":"Song","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2012-07-409755","article-title":"The split personality of regulatory T cells in HIV infection","volume":"121","author":"Chevalier","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.it.2026.06.005_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003319","article-title":"Regulatory T cells negatively affect IL-2 production of effector T cells through CD39\/adenosine pathway in HIV infection","volume":"9","author":"Jenabian","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2026.06.005_bb0250","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/imm.12053","article-title":"Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity","volume":"138","author":"Challier","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.it.2026.06.005_bb0255","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.1900765","article-title":"Adenosine receptor signaling targets both PKA and Epac pathways to polarize dendritic cells to a suppressive phenotype","volume":"203","author":"Kayhan","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0260","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1096\/fj.11-190934","article-title":"Adenosine promotes alternative macrophage activation via A2A and A2B receptors","volume":"26","author":"Cs\u00f3ka","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.it.2026.06.005_bb0265","article-title":"Adenosine-A2A receptor pathway in cancer immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.it.2026.06.005_bb0275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","volume":"24","author":"Vignali","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0285","doi-asserted-by":"crossref","DOI":"10.1177\/15593258251371484","article-title":"adenosine concentration determination for in vitro tumor microenvironment simulation","volume":"23","author":"Chen","year":"2025","journal-title":"Dose-Response"},{"key":"10.1016\/j.it.2026.06.005_bb0290","doi-asserted-by":"crossref","first-page":"20418","DOI":"10.1039\/D5RA02235E","article-title":"Therapeutic potential of adenosine receptor modulators in cancer treatment","volume":"15","author":"Maity","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.it.2026.06.005_bb0295","first-page":"2602","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0300","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2026.06.005_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1003512","article-title":"A prognostic signature based on adenosine metabolism related genes for ovarian cancer","volume":"12","author":"Liang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.it.2026.06.005_bb0310","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.trecan.2021.04.008","article-title":"Extracellular ATP and adenosine in cancer pathogenesis and treatment","volume":"7","author":"Chiarella","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111281","article-title":"Metabolic crosstalk: extracellular ATP and the tumor microenvironment in cancer progression and therapy","volume":"121","author":"Shukla","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.it.2026.06.005_bb0320","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0325","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.it.2026.06.005_bb0330","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41419-022-05319-1","article-title":"Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.it.2026.06.005_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.106059","article-title":"Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines","volume":"123","author":"Cheng","year":"2026","journal-title":"EBioMedicine"},{"key":"10.1016\/j.it.2026.06.005_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.411","article-title":"Extracellular ATP and P\u2082X\u2087 receptor exert context-specific immunogenic effects after immunogenic cancer cell death","volume":"7","author":"Garg","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.it.2026.06.005_bb0345","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10555-007-9054-2","article-title":"Hypoxia-dependent anti-inflammatory pathways in protection of cancerous tissues","volume":"26","author":"Lukashev","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.it.2026.06.005_bb0350","doi-asserted-by":"crossref","first-page":"E9640","DOI":"10.1073\/pnas.1809695115","article-title":"Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment","volume":"115","author":"Lan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2026.06.005_bb0355","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4049\/jimmunol.1003884","article-title":"Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production","volume":"187","author":"Clayton","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/cei.12354","article-title":"Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells","volume":"177","author":"Schuler","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0365","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004043","article-title":"Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents","volume":"10","author":"Turiello","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0370","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/eji.201242909","article-title":"CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function","volume":"43","author":"Smyth","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0375","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.it.2026.06.005_bb0380","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/2159-8290.CD-20-0387","article-title":"Metastasis and immune evasion from extracellular cGAMP hydrolysis","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.06.005_bb0385","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2313693120","article-title":"ENPP1 is an innate immune checkpoint of the anticancer cGAMP\u2013STING pathway in breast cancer","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2026.06.005_bb0390","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.it.2026.06.005_bb0395","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hum.2021.050","article-title":"Adenosine deaminase 1 overexpression enhances the antitumor efficacy of chimeric antigen receptor-engineered T cells","volume":"33","author":"Qu","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.it.2026.06.005_bb0400","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/2326-6066.CIR-22-0565","article-title":"Immunogenetic metabolomics reveals key enzymes that modulate CAR T-cell metabolism and function","volume":"11","author":"Renauer","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.it.2026.06.005_bb0405","article-title":"Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.it.2026.06.005_bb0410","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/0008-5472.CAN-24-1875","article-title":"Adenosine uptake through the nucleoside transporter ENT1 suppresses antitumor immunity and T-cell pyrimidine synthesis","volume":"85","author":"Allard","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2026.100031","article-title":"Adenosine signaling promotes double-negative T-cell anticancer responses in conditions of CD8 T-cell lymphopenia","volume":"2","author":"Huang","year":"2026","journal-title":"Blood Immunol. Cell Ther."},{"key":"10.1016\/j.it.2026.06.005_bb0420","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0425","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1078-0432.CCR-24-3934","article-title":"Adenosine A2B receptor promotes tumor progression and metastases in undifferentiated pleomorphic sarcoma","volume":"32","author":"Ceruso","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116863","article-title":"Activated CD38+ mast cells promote gastric cancer progression by suppressing CD8+ T cell cytotoxic activity through adenosine metabolism","volume":"45","author":"Zhao","year":"2026","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2026.06.005_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101272","article-title":"Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer","volume":"82","author":"Ding","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.it.2026.06.005_bb0440","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0445","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.it.2026.06.005_bb0450","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18440","article-title":"Durvalumab alone or combined with novel agents for unresectable stage iii non\u2013small cell lung cancer: update from the COAST randomized clinical trial","volume":"8","author":"Aggarwal","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.it.2026.06.005_bb0455","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II neocoast platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.06.005_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116028","article-title":"Small molecular CD73 inhibitors: recent progress and future perspectives","volume":"264","author":"Ge","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.it.2026.06.005_bb0465","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1021\/acs.jmedchem.9b01713","article-title":"Discovery of potent and selective non-nucleotide small molecule inhibitors of CD73","volume":"63","author":"Beatty","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2026.06.005_bb0470","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-024-01019-5","article-title":"A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death","volume":"14","author":"Ray","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.it.2026.06.005_bb0475","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1535-7163.MCT-21-0802","article-title":"Targeting CD73 with AB680 (Quemliclustat), a novel and potent small-molecule CD73 inhibitor, restores immune functionality and facilitates antitumor immunity","volume":"21","author":"Piovesan","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.it.2026.06.005_bb0480","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/2472555217750386","article-title":"A robust multiplex mass spectrometric assay for screening small-molecule inhibitors of CD73 with diverse inhibition modalities","volume":"23","author":"McManus","year":"2018","journal-title":"SLAS Discov."},{"key":"10.1016\/j.it.2026.06.005_bb0485","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-20-0076","article-title":"Dual mechanisms of novel CD73-targeted antibody and antibody\u2013drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function","volume":"19","author":"Jin","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.it.2026.06.005_bb0490","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.actbio.2024.09.033","article-title":"Dual immunostimulatory CD73 antibody-polymeric cytotoxic drug complex for triple negative breast cancer therapy","volume":"189","author":"Xie","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.it.2026.06.005_bb0495","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS2675","article-title":"A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1\/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors","volume":"39","author":"Markman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.it.2026.06.005_bb0500","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1158\/1078-0432.CCR-25-2406","article-title":"Sym024 interacts with a unique epitope on the CD73 homodimer, favoring effective bivalent binding to improve anti-PD-1 therapy","volume":"32","author":"Jakobsen","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0505","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1021\/acs.jmedchem.4c00553","article-title":"Discovery of small and bifunctional molecules targeting PD-L1\/CD73 for cancer dual immunotherapy","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.it.2026.06.005_bb0510","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004554","article-title":"Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity","volume":"10","author":"Gammelgaard","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0515","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2021.08.037","article-title":"Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles","volume":"521","author":"Ploeg","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.it.2026.06.005_bb0520","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005267","article-title":"Phase 1 first-in-human study of dalutrafusp alfa, an anti\u2013CD73-TGF-\u03b2-trap bifunctional antibody, in patients with advanced solid tumors","volume":"11","author":"Tolcher","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0525","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41401-021-00840-z","article-title":"Therapeutic efficacy and mechanism of CD73-TGF\u03b2 dual-blockade in a mouse model of triple-negative breast cancer","volume":"43","author":"Xing","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.it.2026.06.005_bb0530","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73699","article-title":"Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors","volume":"11","author":"Chambers","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.it.2026.06.005_bb0535","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","article-title":"Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells","volume":"6","author":"Wang","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189443","article-title":"The CD39-CD73-adenosine axis: master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma","volume":"1880","author":"Liu","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2026.102353","article-title":"Targeted CD73 silencing extracellular vesicles enhance CLL1 cart cell function by improving persistence and reducing exhaustion in aml models","volume":"28","author":"Mill\u00e1n-L\u00f3pez","year":"2026","journal-title":"Cytotherapy"},{"key":"10.1016\/j.it.2026.06.005_bb0550","doi-asserted-by":"crossref","first-page":"S728","DOI":"10.1016\/j.annonc.2020.08.1193","article-title":"1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab \u00b1 oleclumab in advanced solid tumours","volume":"31","author":"Powderly","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.it.2026.06.005_bb0555","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.it.2026.06.005_bb0560","doi-asserted-by":"crossref","first-page":"CT119","DOI":"10.1158\/1538-7445.AM2017-CT119","article-title":"Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors","volume":"77","author":"Emens","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0565","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0570","first-page":"A58","article-title":"52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial","volume":"12","author":"Kim","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.it.2026.06.005_bb0575","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1021\/acsptsci.5c00057","article-title":"Insights from clinical trials on A2A adenosine receptor antagonists for cancer treatment","volume":"8","author":"Deb","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.it.2026.06.005_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.900023","article-title":"Adenosine concentration in patients with neurally mediated syncope","volume":"9","author":"Groppelli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.it.2026.06.005_bb0585","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012228","article-title":"Evaluation of plasma adenosine as a marker of cardiovascular risk: analytical and biological considerations","volume":"8","author":"Simard","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.it.2026.06.005_bb0590","series-title":"Adenosine Receptors: Therapeutic Aspects for Inflammatory and Immune Diseases","author":"Hasko","year":"2006"},{"key":"10.1016\/j.it.2026.06.005_bb0595","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00640-23","article-title":"Damage response signaling by the extracellular adenosine pathway: control of infection outcome during host aging","volume":"10","author":"Bhalla","year":"2025","journal-title":"Msphere"},{"key":"10.1016\/j.it.2026.06.005_bb0600","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/s41590-024-01875-0","article-title":"Distinct SIV-specific CD8+ T cells in the lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence","volume":"25","author":"Strongin","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0605","article-title":"Reversal of the CD8+ T-cell exhaustion induced by chronic HIV-1 infection through combined blockade of the adenosine and PD-1 pathways","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0610","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.jaci.2017.08.021","article-title":"CD8+ CD28\u2212 CD127loCD39+ regulatory T-cell expansion: a new possible pathogenic mechanism for HIV infection?","volume":"141","author":"Fenoglio","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002110","article-title":"CD39\/adenosine pathway is involved in AIDS progression","volume":"7","author":"Nikolova","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.it.2026.06.005_bb0620","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/QAD.0b013e328360c7f3","article-title":"CD4+ CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression","volume":"27","author":"Schuler","year":"2013","journal-title":"Aids"},{"key":"10.1016\/j.it.2026.06.005_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113285","article-title":"The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency","volume":"42","author":"Sperber","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2026.06.005_bb0630","article-title":"Decreased CD73+ double-negative T cells and elevated level of soluble CD73 correlated with and predicted poor immune reconstitution in HIV-infected patients after antiretroviral therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867167","article-title":"Inversed ratio of CD39\/CD73 expression on \u03b3\u03b4 T cells in HIV versus healthy controls correlates with immune activation and disease progression","volume":"13","author":"Kolbe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0640","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1128\/JVI.01196-15","article-title":"Critical role for the adenosine pathway in controlling simian immunodeficiency virus-related immune activation and inflammation in gut mucosal tissues","volume":"89","author":"He","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.it.2026.06.005_bb0645","doi-asserted-by":"crossref","DOI":"10.1093\/jleuko\/qiae192","article-title":"Attenuation of HIV-specific T cell responses among people with HIV on ART following dipyridamole treatment","volume":"117","author":"Morris","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.it.2026.06.005_bb0650","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2567.2009.03121.x","article-title":"Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation","volume":"128","author":"Martinez-Navio","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.it.2026.06.005_bb0655","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4757-9613-1_24","article-title":"HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to human CD26","volume":"421","author":"Valenzuela","year":"1997","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.it.2026.06.005_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.946871","article-title":"CD38+ CD39+ NK cells associate with HIV disease progression and negatively regulate T cell proliferation","volume":"13","author":"Qian","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0665","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: international AIDS society global scientific strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2026.06.005_bb0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101412","article-title":"Immunological approaches to HIV cure","volume":"51","author":"Ward","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0675","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2055-6640(20)30490-8","article-title":"HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?","volume":"1","author":"Kulpa","year":"2015","journal-title":"J. Virus Erad."},{"key":"10.1016\/j.it.2026.06.005_bb0680","article-title":"The role of innate immunity in natural elite controllers of HIV-1 infection","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0685","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41577-025-01136-7","article-title":"Immune-mediated strategies to solving the HIV reservoir problem","volume":"25","author":"Kulpa","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0690","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","article-title":"CD8+ T cells in HIV control, cure and prevention","volume":"20","author":"Collins","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0695","article-title":"The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine","author":"Kutzler","year":"2024","journal-title":"Res. Sq."},{"key":"10.1016\/j.it.2026.06.005_bb0700","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/icb.2009.53","article-title":"Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV","volume":"87","author":"Climent","year":"2009","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.it.2026.06.005_bb0705","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1138609","article-title":"Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge","volume":"14","author":"Gary","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.it.2026.06.005_bb0710","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/0008-5472.CAN-21-0340","article-title":"Targeting adenosine with adenosine deaminase 2 to inhibit growth of solid tumors","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.it.2026.06.005_bb0715","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.7150\/thno.108931","article-title":"Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy","volume":"15","author":"Zhu","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.it.2026.06.005_bb0720","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s42255-020-0219-4","article-title":"Inosine is an alternative carbon source for CD8+-T cell function under glucose restriction","volume":"2","author":"Wang","year":"2020","journal-title":"Nat. Metab."}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626001614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471490626001614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:49:09Z","timestamp":1786481349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490626001614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":144,"alternative-id":["S1471490626001614"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2026.06.005","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenosine as a metabolic checkpoint in CD8+ T cell dysfunction","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}